RFM News and Press, RiverNorth Flexible Municipal Income Fund Inc. From 02/01/24

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the recruitment of the last patient ...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the Association...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces that Federico Mingozzi, Ph.D., is jo...

2024-01-21 18:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Sensorion has received approval to initiate Phase 1/2 clinical trial of SENS-501 (OTOF-GT) in France as first country SENS-501 is Sensorion’s lead gene therapy candidate. It aims at restoring hearing in patients with mutations in the OTOF gene, suffering from severe to profound...

The framework extension agreement underlines the successful collaboration between Sensorion and the Institut Pasteur, involving the Hearing Institute, a research center of the Institut Pasteur, focused on the development of gene therapy programs Two gene therapy development programs a...

2024-01-03 11:16:41 ET More on RiverNorth Flexible Municipal Income Fund Dividend scorecard for RiverNorth Flexible Municipal Income Fund For further details see: RiverNorth Flexible Municipal Income Fund dividend declines by 3.1% to $0.0954

2023-12-24 07:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the results of resolut...

Preliminary data demonstrate that SENS-401 has a favorable safety profile when administered continuously for up to 11 weeks in adult patients undergoing cisplatin-based chemotherapy Recruitment is progressing well, with over a third of the required study population enrolled ...